Unlocking personalised, preventative healthcare
GeneType is transforming healthcare from the one-size-fits-all model to a personalised, preventive approach.
By developing the next generation of integrated predictive genetic testing and assessment tools, we are empowering medical practitioners and their patients to proactively manage health.
Genetics for Life
GeneType’s mission is simple: to provide personalised, preventative healthcare solutions that may help individuals and their medical practitioners screen and reduce the risk of life-changing serious diseases.
Our publication record reflects the
scientific rigour behind our tests.
The health effects in the US of quarantine policies based on predicted individual risk of severe COVID-19 outcomes.
Sam Lovick, Gillian S. Dite, Richard Allman. medRxiv 2021.03.21.21254065
A streamlined model for use in clinical breast cancer risk assessment maintains predictive power and is further improved with inclusion of a polygenic risk score.
Allman R, Spaeth E, Lai J, Gross SJ, Hopper JL.
PLoS One. 2021 Jan 22;16(1):e0245375. doi: 10.1371/journal.pone.0245375. eCollection 2021.
An integrated clinical and genetic model for predicting risk of severe COVID-19: A population-based case-control study.
PLoS One. 2021 Feb 16;16(2):e0247205. doi: 10.1371/journal.pone.0247205. eCollection 2021.
Ability of known colorectal cancer susceptibility SNPs to predict colorectal cancer risk: A cohort study within the UK Biobank.
Gafni A, Dite GS, Spaeth Tuff E, Allman R, Hopper JL.
PLoS One. 2021 Sep 15;16(9):e0251469. doi: 10.1371/journal.pone.0251469. eCollection 2021.
Development and validation of a clinical and genetic model for predicting risk of severe COVID-19.
Dite GS, Murphy NM, Allman R.
Epidemiol Infect. 2021 Jul 2;149:e162. doi: 10.1017/S095026882100145X.
Bridging the Data Gap in Breast Cancer Risk Assessment to Enable Widespread Clinical Implementation across the Multiethnic Landscape of the US.
Spaeth E, Starlard-Davenport A, Allman R.
J Cancer Treatment Diagn. 2018;2(4):1-6. doi: 10.29245/2578-2967/2018/4.1137. Epub 2018 Aug 3.
Validation of a genetic risk score for Arkansas women of color.
Starlard-Davenport A, Allman R, Dite GS, Hopper JL, Spaeth Tuff E, Macleod S, Kadlubar S, Preston M, Henry-Tillman R.
PLoS One. 2018 Oct 3;13(10):e0204834. doi: 10.1371/journal.pone.0204834. eCollection 2018.
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry.
Dite GS, MacInnis RJ, Bickerstaffe A, Dowty JG, Allman R, Apicella C, Milne RL, Tsimiklis H, Phillips KA, Giles GG, Terry MB, Southey MC, Hopper JL.
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):359-65. doi: 10.1158/1055-9965.EPI-15-0838. Epub 2015 Dec 16.
SNPs and breast cancer risk prediction for African American and Hispanic women.
Allman R, Dite GS, Hopper JL, Gordon O, Starlard-Davenport A, Chlebowski R, Kooperberg C.
Breast Cancer Res Treat. 2015 Dec;154(3):583-9. doi: 10.1007/s10549-015-3641-7. Epub 2015 Nov 20.
Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy.
Green LE, Dinh TA, Hinds DA, Walser BL, Allman R (2014). Applied Health Economics & Health Policy. 12(2): 203-17
Cost-effectiveness of a genetic test for breast cancer risk.
Folse HJ, Green LE, Kress A, Allman R, Dinh TA.
Cancer Prev Res (Phila). 2013 Dec;6(12):1328-36. doi: 10.1158/1940-6207.CAPR-13-0056.
Our patented technology sets us apart
Patents granted in US
- Patent 11,031,098, Computer systems and methods for genomic analysis
- Patent 10,683,549, Methods for assessing risk of developing breast cancer
- Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included in the BREVAGenplus® risk assessment test
- Patent No. 7,127,355 offering broad protection re: methods of genetic analysis (the concept of combining clinical risk assessment with genetic risk factors to improve predictability over clinical risk assessment alone)
- Patent No. 6,969,589 covering the identification of informative SNPs
Patents granted in China
- Patent Nos. 200680051710.0; 201310524782.4; 201310524916.2 and 201310524765.0 “Markers for Breast Cancer”
- Patent No. 201080033130.5 Methods for Breast Cancer Risk Assessment
- Patent Nos. 09101235.4; 12112875.1; 12112368.5 and 12112874.2 “Markers for Breast Cancer”
- Patent No. 12109000.5 Methods for Breast Cancer Risk Assessment
Patent families pending
- Methods for breast cancer risk assessment
- Methods for assessing risk of developing breast cancer
- Improved methods for assessing risk of developing breast cancer
- Markers for breast cancer
- Methods for genetic analysis
- Methods for genomic analysis
- Methods for assessing risk of developing colorectal cancer
- Methods of assessing risk developing a disease
- Methods for assessing risk of developing a severe response to coronavirus infection
Keep up-to-date with our latest advances
Sign up to our newsletter to stay informed about our latest advances and how these could support you.
